About Acomplia 20mg:
 Acomplia is the preparation on the basis of the rimonabant, produced by the Sanofi-Aventis pharmaceutical company and licensed for sale in all the 25 countries of the European Union according to the European Commission resolution dated June 21, 2006. It is the first of the CB1 blockers, recommended as the bariatrics means or obesity treatment means in patients with such associated risk factors as diabetes mellitus type 2 or dyslipidemia. As a rule, buy acomplia is recommended in combination with a special diet and exercising.
Pharmacological properties: The active component of the Acomplia is the rimonabant - selective cannabinoid receptor antagonist-1, inhibiting the pharmacological effects of the cannabinoid agonists. Endocannabinoid system as the physiological system of the human body, presented in the brain and peripheral tissues including adipocytes, deals with the energy balance and glucose and lipids metabolism into the human body weight and regulates the foodstuffs (such as flavored food, sweet or fatty food) consumption on the mesolimbic system neurons level.
The rimonabant pharmacokinetics depends on the rimonabant (Acomplia) dosage and changes in proportion to the Acomplia 20mg dose alterations (in case the rimonabant dose is not more than 20 mg).
Dosage and Method of Application: The recommended Acomplia dose for the adult patients is 20 mg a day (1 pill) in the morning before breakfast. The strict observance by the patient of the dosage prescribed is obligatory. The buy acomplia 20mg therapy should be combined and started simultaneously with the moderate low-calorie diet.
The Acomplia therapy duration period is determined by the doctor.
The Acomplia dose adjustment in aged patients is not needed. In patients aged more than 75 buy Acomplia should be taken with great care. The patients with mild or average hepatic (liver) failure or mild or average renal failure do not need any Acomplia dose adjustments in case of buy Acomplia online therapy. For the patients with serious hepatic (liver) failure and serious renal failure the Acomplia therapy is not recommended.
|
